You are here

Dana-Farber Cancer Institute

Member Since 2017

Laurie H. Glimcher, MD

President and Chief Executive Officer

Dana-Farber L. Glimcher

Laurie H. Glimcher, MD, became the president and chief executive officer of the Institute in October 2016 and also serves as chief executive officer of Dana-Farber/Partners CancerCare, director of Dana-Farber/Harvard Cancer Center, and a trustee of Dana-Farber/Children's Hospital Cancer Care. Dr. Glimcher is the Richard and Susan Smith Professor of Medicine and a professor of Microbiology and Immunobiology at Harvard Medical School. She received a bachelor's degree, magna cum laude, from Radcliffe College and a medical degree, cum laude, from Harvard Medical School.

Immediately prior to assuming the presidency of the Institute, Dr. Glimcher served as the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medical College in New York City, and Provost for Medical Affairs of Cornell University. From 1991-2011, Dr. Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, where she was director of the Division of Biological Sciences, and Professor of Medicine at Harvard Medical School, where she headed one of the top immunology programs in the world.

Dr. Glimcher is the recipient of many awards and honors. Most recently, she received the Indiana University School of Medicine's Steven C. Beering Award for outstanding research contributions to advancement of biomedical or clinical science; the L'Oréal-UNESCO Award for Women in Science; the 2017 George M. Kober Medal; and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges (AAMC).

Dr. Glimcher has made numerous discoveries that have advanced treatments for many diseases and chronic conditions, including cancer, asthma, and osteoporosis. She is widely considered to be the international authority on the development and activation of lymphocytes in the immune system.

As an immunologist, her primary research interests are elucidating the molecular pathways that regulate the immune system, critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. She is a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine and a Member of the National Academy of Sciences. She sits on the Board of Trustees of the Parker Institute for Cancer Immunotherapy and on the Corporate Board of Directors of the Waters Corporation and GlaxoSmithKline plc.

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2009

Gold Standard  Task Force Participation

Task Force Member(s): Anne L. Levine, Vice President of External Affairs

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): George Demetri, MD, Cancer Center Associate Director for Clinical Sciences

Dana-Farber Cancer Institute

Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.